MA31895B1 - (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates - Google Patents
(alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonatesInfo
- Publication number
- MA31895B1 MA31895B1 MA32880A MA32880A MA31895B1 MA 31895 B1 MA31895 B1 MA 31895B1 MA 32880 A MA32880 A MA 32880A MA 32880 A MA32880 A MA 32880A MA 31895 B1 MA31895 B1 MA 31895B1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- treatment
- compounds
- alkyl
- branched
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
- 229940122361 Bisphosphonate Drugs 0.000 title 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000013823 prenylation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'INVENTION PORTE SUR DES ACIDES [(IMIDAZOL-1-YL)-1-HYDROXY-1-PHOSPHONOÉTHYL] PHOSPHONIQUES SUBSTITUÉS PAR ALKYLE EN C2-C5, AINSI QUE SUR DES MÉTHODES OU DES PROCÉDÉS PERMETTANT DE LES FABRIQUER, SUR LEUR UTILISATION DANS LA FABRICATION DE FORMULATIONS PHARMACEUTIQUES, SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES, SUR DES PROCÉDÉS D'UTILISATION DE CEUX-CI DANS LE TRAITEMENT DE MALADIES, SUR DES FORMULATIONS PHARMACEUTIQUES LES ENGLOBANT ET/OU SUR LES COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES. LES COMPOSÉS SONT CAPABLES D'INHIBER UNE RÉSORPTION OSSEUSE EXCESSIVE OU INAPPROPRIÉE ET SONT APPROPRIÉS POUR LE TRAITEMENT D'AUTRES MALADIES QUI SONT PROVOQUÉES PAR UNE PRÉNYLATION EXCESSIVE DE PROTÉINES CIBLES, TELLES QUE LE SYNDROME DE PROGÉRIE D'HUTCHINSON-GILFORD. LES COMPOSÉS SONT REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE L'UN PARMI R1 ET R2 REPRÉSENTE HYDROGÈNE ET L'AUTRE REPRÉSENTE ALKYLE EN C2-C5 QUI EST RAMIFIÉ OU NON RAMIFIÉ, ET PEUVENT SE PRÉSENTER SOUS UNE FORME LIBRE, SOUS LA FORME D'UN ESTER ET/OU D'UN SEL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07122016 | 2007-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31895B1 true MA31895B1 (fr) | 2010-12-01 |
Family
ID=39154111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32880A MA31895B1 (fr) | 2007-11-30 | 2010-05-31 | (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7977323B2 (fr) |
| EP (1) | EP2225252B1 (fr) |
| JP (1) | JP5244917B2 (fr) |
| KR (1) | KR20100092035A (fr) |
| CN (1) | CN101835787A (fr) |
| AR (1) | AR069437A1 (fr) |
| AU (1) | AU2008328797B2 (fr) |
| BR (1) | BRPI0819902A2 (fr) |
| CA (1) | CA2701516A1 (fr) |
| CL (1) | CL2008003545A1 (fr) |
| CO (1) | CO6280421A2 (fr) |
| CR (1) | CR11362A (fr) |
| EA (1) | EA201000860A1 (fr) |
| EC (1) | ECSP10010321A (fr) |
| ES (1) | ES2386851T3 (fr) |
| IL (1) | IL204657A0 (fr) |
| MA (1) | MA31895B1 (fr) |
| MX (1) | MX2010005786A (fr) |
| NZ (1) | NZ584219A (fr) |
| PE (1) | PE20091038A1 (fr) |
| TN (1) | TN2010000138A1 (fr) |
| TW (1) | TW200932248A (fr) |
| WO (1) | WO2009068567A1 (fr) |
| ZA (1) | ZA201001992B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201001578A1 (ru) * | 2008-04-04 | 2011-06-30 | Новартис Аг | Фармацевтическая композиция с бисфосфонатом |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| ES2650665T3 (es) | 2009-07-31 | 2018-01-19 | Grünenthal GmbH | Método de cristalización y biodisponibilidad |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US8816082B2 (en) | 2010-05-28 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| US9290526B2 (en) | 2010-05-28 | 2016-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
| WO2012071517A2 (fr) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Nouvelles formes cristallines |
| CN102659840B (zh) * | 2012-05-10 | 2013-08-14 | 苏州普瑞诺药物技术有限公司 | 咪唑双膦酸类化合物及其可药用盐及药物用途 |
| WO2017208070A1 (fr) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Acide bisphosphonique et coformeurs avec lysine, glycine, nicotinamide pour le traitement de la polyarthrite psoriasique |
| WO2019076269A1 (fr) | 2017-10-16 | 2019-04-25 | 清华大学 | Inhibiteur de la voie de l'acide mévalonique et composition pharmaceutique correspondante |
| CN112980809B (zh) * | 2021-03-17 | 2023-04-11 | 云南中烟工业有限责任公司 | 一种烟草法尼基焦磷酸合酶基因及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0275821B1 (fr) | 1986-11-21 | 1992-02-26 | Ciba-Geigy Ag | Acides alcanediphosphoniques substitués |
| ATE119777T1 (de) * | 1991-02-26 | 1995-04-15 | Procter & Gamble Pharma | Behandlungsmethoden für osteoporose. |
| GB9324143D0 (en) | 1993-11-24 | 1994-01-12 | Schering Agrochemicals Ltd | Triazole phosphonate pesticides |
| GB0029018D0 (en) * | 2000-11-28 | 2001-01-10 | Strakan Group Plc | Dermatological formulations |
| GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| AU2007304205A1 (en) | 2006-10-05 | 2008-04-10 | Novartis Ag | Pharmaceutical compositions comprising bisphosphonates |
| EP2139888A2 (fr) | 2007-03-28 | 2010-01-06 | Array Biopharma, Inc. | Composés imidazoý1,2-a¨pyridine en tant qu'inhibiteurs de la tyrosine kinase récepteur |
-
2008
- 2008-11-26 CA CA2701516A patent/CA2701516A1/fr not_active Abandoned
- 2008-11-26 EA EA201000860A patent/EA201000860A1/ru unknown
- 2008-11-26 JP JP2010535369A patent/JP5244917B2/ja active Active
- 2008-11-26 CN CN200880112351A patent/CN101835787A/zh active Pending
- 2008-11-26 MX MX2010005786A patent/MX2010005786A/es active IP Right Grant
- 2008-11-26 KR KR1020107014395A patent/KR20100092035A/ko not_active Application Discontinuation
- 2008-11-26 BR BRPI0819902-7A patent/BRPI0819902A2/pt not_active IP Right Cessation
- 2008-11-26 WO PCT/EP2008/066245 patent/WO2009068567A1/fr active Application Filing
- 2008-11-26 EP EP08854485A patent/EP2225252B1/fr active Active
- 2008-11-26 AU AU2008328797A patent/AU2008328797B2/en not_active Ceased
- 2008-11-26 US US12/323,696 patent/US7977323B2/en not_active Expired - Fee Related
- 2008-11-26 ES ES08854485T patent/ES2386851T3/es active Active
- 2008-11-26 NZ NZ584219A patent/NZ584219A/en not_active IP Right Cessation
- 2008-11-27 AR ARP080105163A patent/AR069437A1/es active IP Right Grant
- 2008-11-27 PE PE2008001990A patent/PE20091038A1/es not_active Application Discontinuation
- 2008-11-28 TW TW097146484A patent/TW200932248A/zh unknown
- 2008-11-28 CL CL2008003545A patent/CL2008003545A1/es unknown
-
2010
- 2010-03-19 ZA ZA2010/01992A patent/ZA201001992B/en unknown
- 2010-03-22 IL IL204657A patent/IL204657A0/en unknown
- 2010-03-26 TN TNP2010000138A patent/TN2010000138A1/fr unknown
- 2010-04-09 CR CR11362A patent/CR11362A/es unknown
- 2010-05-26 CO CO10063351A patent/CO6280421A2/es not_active Application Discontinuation
- 2010-05-31 MA MA32880A patent/MA31895B1/fr unknown
- 2010-06-30 EC EC2010010321A patent/ECSP10010321A/es unknown
-
2011
- 2011-05-26 US US13/116,671 patent/US20110224173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011504908A (ja) | 2011-02-17 |
| CL2008003545A1 (es) | 2009-06-05 |
| US20110224173A1 (en) | 2011-09-15 |
| MX2010005786A (es) | 2010-06-09 |
| US7977323B2 (en) | 2011-07-12 |
| TN2010000138A1 (en) | 2011-09-26 |
| CR11362A (es) | 2010-06-14 |
| AU2008328797B2 (en) | 2011-11-03 |
| KR20100092035A (ko) | 2010-08-19 |
| CA2701516A1 (fr) | 2009-06-04 |
| ECSP10010321A (es) | 2010-08-31 |
| BRPI0819902A2 (pt) | 2015-05-19 |
| AR069437A1 (es) | 2010-01-20 |
| WO2009068567A1 (fr) | 2009-06-04 |
| PE20091038A1 (es) | 2009-08-19 |
| US20090143337A1 (en) | 2009-06-04 |
| EP2225252B1 (fr) | 2012-06-27 |
| TW200932248A (en) | 2009-08-01 |
| ES2386851T3 (es) | 2012-09-03 |
| CN101835787A (zh) | 2010-09-15 |
| JP5244917B2 (ja) | 2013-07-24 |
| EP2225252A1 (fr) | 2010-09-08 |
| ZA201001992B (en) | 2010-12-29 |
| AU2008328797A1 (en) | 2009-06-04 |
| IL204657A0 (en) | 2010-11-30 |
| CO6280421A2 (es) | 2011-05-20 |
| NZ584219A (en) | 2012-03-30 |
| EA201000860A1 (ru) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31895B1 (fr) | (alkyl en c<sb>2</sb>-c<sb>5</sb>) imidazole - bisphosphonates | |
| CN110809467B (zh) | Sestrin-gator2相互作用的调节剂及其用途 | |
| MA31766B1 (fr) | Composés organiques | |
| WO2014164867A1 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| MA31284B1 (fr) | Nouveau procede | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| TNSN00202A1 (fr) | Derives de n-[(purine - 2- yl) methyl]-sulfonamide nouveaux, procede pour leur preparation et compositions les contenant | |
| KR20160045079A (ko) | 질환의 치료를 위한 ｋｄｍ１ａ 저해인자 | |
| US20060084695A1 (en) | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | |
| MA33083B1 (fr) | Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament | |
| MA29909B1 (fr) | Derives de pyridazine | |
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA31504B1 (fr) | Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes | |
| CY1111808T1 (el) | Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια | |
| TNSN07070A1 (fr) | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases | |
| MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
| TNSN00092A1 (fr) | Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
| EP1673078A4 (fr) | Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer | |
| EP1887007A3 (fr) | Imidazo- et thiazolopyridines en tant qu'inhibiteurs de la JAK3 kinase | |
| EP1689713A4 (fr) | Inhibiteurs de benzylether et benzylamino de beta-secretase pour traiter la maladie d'alzheimer | |
| MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
| MA32798B1 (fr) | Acides naphtylacétiques |